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Background: Pancreatic cysts are being increasingly identified in patients. Mucinous cysts have malignant potential
whereas non-mucinous cysts do not. Distinguishing potentially malignant cysts from harmless ones by the
characterization of cyst fluid contents remains a difficult problem. This study was undertaken to determine
whether cyst fluid mucin glycoprotein analysis could differentiate mucinous from non-mucinous pancreatic cysts.
Methods: Cyst fluid from 28 patients who underwent resection of a pancreatic cyst was used for the study. In each
case the type of cyst was histologically identified. One dimensional SDS polyacrylamide gel electrophoresis (1D-SDS
PAGE) was performed on cyst fluid samples. For the detection of the separated proteins, we employed a novel dual
staining technique. The gel was first stained with periodic acid Schiff (PAS), a mucin histochemical stain followed by
a secondary protein staining with Simply Blue Safestain (Invitrogen).
Results: Visual scoring (based on the presence of mucins) gave a sensitivity of 95%, a specificity of 100%, a positive
predictive value of 100%, and a negative predictive value of 88% for prediction of mucinous histology.
Conclusions: One dimensional SDS polyacrylamide gel electrophoresis of pancreatic cyst fluid, followed by mucin
(PAS) and protein (Simply Blue Safestain) staining, provides a means of concentrating and visualizing mucins, which
allows the accurate differentiation of mucinous from non-mucinous histology in pancreatic cysts.
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Pancreatic cysts are being increasingly identified by im-
proved imaging methods, including endoscopic ultrasound
(EUS), which allows cyst fluid sampling. Some mucinous
cysts have malignant potential, whereas non-mucinous
cysts do not. Surgical resection is often recommended for
mucinous cystic lesions of the pancreas because of cancer
risk [1,2], but differentiating harmless cysts from poten-
tially malignant ones remains difficult. Whether to resect
or observe certain cysts is a common clinical problem
owing to the inability to distinguish mucinous from non-
mucinous cysts.
Pancreatic neoplasms with malignant potential such as
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unless otherwise stated.neoplasm (IPMN), can be distinguished to some extent,
using cyst fluid analysis techniques, from cysts with no ma-
lignant potential, such as serous cystadenoma and pseudo-
cyst. Cytology of cyst fluid showing dysplastic features is
strongly predictive of mucinous neoplasia but is often
falsely negative [3]. Clinical staining methods looking for
mucin in the cyst fluid of pancreatic cysts have shown vari-
able positivity but are considered unreliable [4,5]. The cyst
fluid carcinoembryeonic antigen (CEA) level has proven
more reliable but is not a consistent positive predictor of
mucinous histology by itself [6].
This research was undertaken to evaluate a pancreas cyst
fluid characteristic that could reliably identify mucinous
histology and therefore help to guide therapy. Mucinous
cystic lesions of the pancreas are known to express mucins
in their cyst fluid [7]. Clinical mucin staining often fails
to identify mucins, either because of dilution, low level of
expression, inhomogeneous distribution within the fluidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 2 Carcinoembryonic Antigen (CEA) levels, compared
to staining scoring
Mucin




P15 (cystic lymphangioma) 0 0 - Negative
Pan19 (serous microcystic adenona) 0 0 - Negative
P64 (lymphoepithelial cyst) 1576** 0 - Negative
Pan18 (pseudocyst) 0 0 - Negative
Pan21 (pseudocyst) 0 0 - Negative
Pan22 (pseudocyst) 0 0 - Negative
P39 (pseudocyst) 0 0 – Negative
Mucinous
P10 (IPMN benign) 994 3 - Positive
P31 (IPMN benign) 106* 2 - Positive
P32 (IPMN benign) 878 1 - Positive
P43 (IPMN benign) 1011 0 -Negative
P46 (IPMN benign) 589 2 - Positive
P56 (IPMN benign) 598 1 - Positive
P4 (IPMN malignant) 555 2 - Positive
P7 (IPMN malignant) 438 1 - Positive
P41 (IPMN malignant) 988 2 - Positive
P55 (IPMN malignant) 589 2 - Positive
P57 (IPMN malignant) 1493 3 - Positive
P58 (IPMN malignant) 654 2 - Positive
P61 (IPMN malignant) 229 2 - Positive
P65 (IPMN malignant) 329 1 – Positive
P68 (IPMN malignant) 26* 1 – Positive
Pan16 (Mucinous cystadenoma) 1572 1 – Positive
P24 (Mucinous cystadenoma) 517 2 - Positive
P25 (Mucinous cystadenoma) 2253 3 - Positive
P40 (Mucinous cystadenoma) 1065 3 - Positive
P63 (Mucinous cystadenoma) 208 2 – Positive
P69 (Mucinous cystadenome) 5 2 – Positive
*False negative; **False positive.
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has shown that mucins are uniformly found in the high
molecular weight region (>250 K daltons) of a one dimen-
sional, polyacrylamide gel [8,9]. Using the technique of one
dimensional, polyacrylamide gel electrophoresis (1D-SDS
PAGE) we were able to separate mucins from smaller pro-
teins within the fluid, concentrating mucins near the origin
of the gel. The dual staining procedure effectively demon-
strated the presence of mucins in the cyst fluid of mucin-
ous cystic lesions.
Results
Results of the stain scoring are shown in Table 1. None
of the non-mucinous cysts showed staining for mucin,
whereas all of the mucinous cystadenomas and 14 of the
15 IPMN specimens (93%) showed positive mucin staining.
As a test for detecting mucinous neoplasms, these results
yielded a sensitivity of 95%, a specificity of 100%, a positive
predictive value of 100%, and a negative predictive value
of 88%. Prediction intervals using a binomial model were
calculated for the number of false negatives and false
positives; under this model each count will be less than
19% of the sample size with a probability of 0.95.
CEA Results (reported as ng/ml) are listed in Table 2.
Using a CEA level of >200 ng/ml to indicate mucinous
histology [10], CEA results had one false positive and
two false negative results.
Four samples did not reach the 5 ug level for protein
loading. All of these were mucinous samples and had
total protein content of 1.95 ug, 1.6 ug, 1.6 ug and 3.2
ug; they were all scored as positive for mucin, with
respective protein scores of 1, 2, 2, and 2.
Discussion
Diagnostic tests of pancreatic cyst fluid that can accurately
predict cyst wall histology are needed in order to differen-
tiate between harmless cystic lesions and premalignant,
mucinous lesions that would require surgical intervention.
Mucicarmine fluid staining for extracellular mucin is a
weak predictor of mucinous histology, with 38% to 55% of
mucinous cystic lesions testing positive, as well as 40% ofTable 1 Histologic diagnosis compared to stain scoring
Total Stain scoring
Histologic diagnosis Number Negative Positive
Non-mucinous cyst
Non-mucinous cyst 3 3
Pseudocyst 4 4
Mucinous cyst
IPMN benign 6 1* 5
IPMN malignant 9 9
Mucinous cystadenoma 6 6
*False negative.pseudocysts [7,11]. It has a reported positive predictive
value of 61% in one study [6]. Cytology of cyst fluid is
strongly predictive of mucinous histology when positive,
but is an insensitive test. [6,10,12]. Cyst fluid CEA level
has shown sensitivity when present in high amounts
[10,12], but its positive predictive value as an independent
test in a large cooperative study was 79% [10] and has
been reported to be as low as 51% by others [6]. Further-
more, investigators use different levels of CEA to pre-
dict mucinous histology in different reports, depending
on whether or not the goal is sensitivity, specificity or
accurate. Exhaustive investigation into the entire cyst fluid
Table 3 Postoperative histologic diagnosis
Histologic diagnosis Number Percent
Non-mucinous cyst 7 25%
Serous microcystic adenoma 1 3.6%
Cystic lymphangioma 1 3.6%
Lymphoepithelial cyst 1 3.6%
Pseudocyst 4 14.3%
Mucinous cyst 21 75%
Mucinous cystadenoma 6 21.4%
IPMN benign 6 21.4%
IPMN malignant 9 34.2%
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biomarkers any more useful than the CEA level [5,13].
1-D SDS PAGE of pancreatic cyst fluid, utilizing a single
protein specific stain (SYPRO Ruby fluorescence), has been
employed by others with no demonstrable diagnostic value
[8]. Specific cyst fluid (non-mucinous) glycoproteins have
shown some promise as biomarkers for mucinous hist-
ology, with independent sensitivity in one study as high
as 78% [8].
The 1-D SDS PAGE/mucin staining method we have
described, shows a high sensitivity, specificity, positive
predictive value, and negative predictive value for detecting
mucinous neoplasms. This is due to the separation of
mucin glycoproteins from other proteins and their concen-
tration on the gel.
Protein electrophoresis is commonly employed in clinical
laboratories. This makes it possible that this method could
be converted to a diagnostic test for clinical use.Figure 1 1-D SDS PAGE; primary PAS glycoprotein staining of represe
is downward).The visual scoring of mucin content is a weakness in
the analysis. The use of densitometry or quantitation of
the mucin glycoprotein levels might allow a more accur-
ate evaluation. Nonetheless, visual scoring methods,
such as the one that we employed, are often used in clin-
ical medicine. The Her2 Neu staining for breast cancer,
which is visually scored 0 to 3+ based on an estimate of
immunohistochemistry staining of cell membranes, is
considered a reliable clinical tool. CEA levels continue
to be the used as the primary clinical biomarker of mu-
cinous cystic lesions. While CEA level was not part of
our primary data analysis, the results are included as an
interesting clinical correlation.
The expanding field of glycoproteomics makes use of
mass spectrometry (MS) to analyze complex biologic
fluids such as pancreatic cyst fluid. It requires the
enrichment of the mucin glycoprotein content in the
fluid to allow MS to identify peptides expressed in low
concentrations. A number of methods have been used to
achieve this enrichment, including lectin affinity chro-
matography, hydrophilic solid phase extraction, boric
acid, and hydrazide chemistry [14,15]. The 1-D SDS
PAGE/ dual staining technique presented herein displays
the ability to effectively enrich the mucin glycoprotein in
the samples, which should aid in further proteomic
analyses of these cysts.
Our ongoing research to identify specific mucins
present in pancreatic cyst fluid, using MS, could enable
more exact differentiation between the various mucinous
and non-mucinous cyst types. Particular mucins identified
within the cyst fluid may prove to be useful as biomarkers




Figure 2 1-D SDS PAGE; dual stained pancreatic cyst fluid samples (PAS and SimplyBlue).
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Pancreatic cyst fluid, which often shows a high degree of
variation from one sample to the next, is difficult to analyze.
The technique of one dimensional SDS polyacrylamide gel
electrophoresis of the pancreatic cyst fluid, followed by
dual staining for mucin (PAS) and protein (Simply Blue
Safestain), provides a means of concentrating and visu-
alizing the mucins. This allows the accurate differenti-
ation of mucinous from non-mucinous histology in
pancreatic cysts.
Methods
Samples: Between November 2005 and January 2011,
twenty-eight fluid samples were obtained from patients
with surgically excised cystic pancreatic lesions, under an
IRB approved protocol for the purpose of this research.
Each lesion had an unequivocal histological diagnosis on
postoperative pathologic examination, as listed in Table 3.
All IPMN samples categorized as benign displayed low-Figure 3 Close up of representative lane origins and the purple, dual
each specimen.grade dysplasia by definition. Those cases of IPMN
displaying high-grade dysplasia were categorized as malig-
nant. Fluid samples were obtained by a single investigator
(JMS) in the course of operative resection, either from the
in situ specimen or immediately upon removal of the
cyst from the patient. The fluid samples were frozen
immediately within dry ice in plastic containers and
then transferred directly to a minus 70 degree freezer
at the conclusion of the operation. Pseudocysts were
treated with enteric drainage, but a portion of the
pseudocyst cyst wall was sent for histology, and all of
these cysts resolved following treatment.
Sample preparation
Each sample was thawed and vortexed to ensure thorough
mixing. An aliquot was removed and the sample refrozen.
Protein content of the fluid was determined using the
Pierce BCA protein assay kit (Thermo Scientific, Rockford
IL), and 5 ug of protein used, as this is a commonlystained bands used for scoring. Visual staining scores are above
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during electrophoresis. In samples where the protein con-
centration was too low to reach the 5 ug level (N = 4 of 28),
the maximum volume for gel loading (6.5 ul) was used.
Electrophoresis
Cyst fluid samples were run on a 4-12% NuPage Novex
Bis-tris minigels (Invitrogen, Carlsbad CA) with MES (2-
morpholinoethanesulfonic acid) running buffer containing
50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA at
pH 7.3.
Samples were run under reducing conditions, prepared
by combining the sample with 2.5 ul NuPage sample
buffer (4×), 1ul NuPage reducing agent (10×), and then
brought to a final volume of 10 ul. Samples were heated to
70 degrees C for 10 minutes (as per manufactures protocol),
vortexed, spun down and loaded on the gel. The gel was
then run at 200 volts constant for 35 minutes.
Staining
Primary staining was done with periodic acid-Schiff (PAS).
Following electrophoresis the gel was immersed in 12.5%
trichloracetic acid for 20 minutes, then 1% periodic acid
for 25 minutes in the dark. It was then immersed in
Schiff ’s fuchsin-sulfite reagent (Sigma-Aldrich, St. Louis
MO) for 15 minutes in the dark, washed in 0.5% metabi-
sulfate twice and then washed in water until the gel
destained. The gel was then photographed. As seen in
Figure 1, results showed red staining of the glycoproteins.
The secondary stain utilized the SimplyBlue SafeStain
(Invitrogen, Carlsbad CA). Following PAS staining the
gel was placed in 100 ml of water and microwaved to
almost boiling; the water was then discarded, with this
process repeated twice. The gel was then covered with
SimplyBlue SafeStain and microwaved about 1.5 minutes,
washed in 100 ml water and then 20 ml of 20% NaCl was
added for 5 minutes. The gel was then photographed. The
results showed blue staining of all proteins and purple
(red primary and blue secondary) staining of glycoproteins
(Figures 2 and 3).
Glycoprotein stain scoring
The dual stained gels were visually assessed by an evaluator
blinded to the cyst fluid histology. The degree of mucin
staining was accessed immediately downstream of the well.
Staining at the 0 level was designated negative for mucin.
Any detectable mucin staining was designated as positive
and given a +1, +2 or +3 valuation (Figures 2 and 3).
Carcinoembryonic Antigen (CEA)
The carcinoembryonic antigen (CEA) in each fluid sample
was determined using an enzyme-linked immunosorbent
assay (ELISA) kit for CEA (ALPCO, Salem NH) as per
manufacturer’s protocol.Statistical analysis
Binomial distribution prediction intervals were calculated
for the false positive and false negative rates using the
technique of Krishnamoorthy [16].
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